Skip to Content
Merck
CN
  • CD44v6 promotes β-catenin and TGF-β expression, inducing aggression in ovarian cancer cells.

CD44v6 promotes β-catenin and TGF-β expression, inducing aggression in ovarian cancer cells.

Molecular medicine reports (2015-01-13)
Jing Wang, Ling Xiao, Chen-Hui Luo, Hui Zhou, Liang Zeng, Jingmin Zhong, Yan Tang, Xue-Heng Zhao, Min Zhao, Yi Zhang
ABSTRACT

A high expression of CD44v6 has been reported in numerous malignant cancers, including stomach, prostate, lung and colon. However, the pathological role and the regulatory mechanisms of CD44v6 have yet to be elucidated. In the present study, the expression levels of CD44v6 were shown to be significantly higher in ovarian cancer tissues, as compared with adjacent normal tissues. Furthermore, the upregulated expression levels of CD44v6 were correlated with disease recurrence and poor survival in patients. The expression of CD44v6 was knocked down in the CAOV3 ovarian cell line, by transfection of a specific small hairpin RNA. The present study showed a correlation between the aggression, viability, invasion and migration of the ovarian cancer cells, with the expression of CD44v6. In addition, the expression of CD44v6 was positively correlated with the expression levels of β‑catenin and tumor growth factor‑β, which indicates that the effects of CD44v6 on ovarian cancer cell aggression may be mediated by these two signaling pathways. In conclusion, the present study provides a novel insight into the association between CD44v6 expression and ovarian cancer. CD44v6 may provide a novel target for the prognosis and treatment of ovarian cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-TGF β1 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-β-Catenin antibody produced in rabbit, whole antiserum
Sigma-Aldrich
Anti-CD44 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution